[I-123] ADAM and SPECT in patients with borderline personality disorder and healthy control subjects

Journal of Psychiatry and Neuroscience

Volumn 32, Issue 4, 2007, Pages 234-240

  Koch, Walter ^a   Schaaff, Nadine ^b   Pöpperl, Gabriele ^a   Mulert, Christoph ^b   Juckel, Georg ^c   Reicherzer, Markus ^d   Ehmer von Geiso, Christoff ^e   Möller, Hans Jürgen ^b   Hegerl, Ulrich ^b   Tatsch, Klaus ^a   Pogarell, Oliver ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d Center of Psychosomatic Medicine   (Germany)

^e Clinic for Pneumology and Gastroenterology   (Germany)

Author keywords

Borderline personality disorder; Impulsive behaviour; Serotonin transporter; Single photon emission computed tomography

Indexed keywords

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BINDING AFFINITY; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HYPOTHALAMUS; IMPULSIVENESS; PERSONALITY DISORDER; SEROTONIN BRAIN LEVEL; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 34447313460     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Skodol AE, Gunderson JG, Pfohl B, et al. The borderline diagnosis I: psychopathology, comorbidity, and personality structure. Biol Psychiatry 2002;51:936-50.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington: The Association; 1994.
3. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 2001;58:590-6.
4. Soloff PH, Lynch KG, Kelly TM, et al. Characteristics of suicide attempts of patients with major depressive episode and borderline personality disorder: a comparative study. Am J Psychiatry 2000;157:601-8.
5. American Psychiatric Association. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 2001;158(10S):1-52.
6. Soloff PH, Meltzer CC, Becker C, et al. Impulsivity and prefrontal hypometabolism in borderline personality disorder. Psychiatry Res 2003;123:153-63.
7. Juengling FD, Schmahl C, Hesslinger B, et al. Positron emission tomography in female patients with borderline personality disorder. J Psychiatr Res 2003;37:109-15.
8. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 1989; 46:587-99.
9. Rinne T, Westenberg HG, den Boer JA, et al. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry 2000;47:548-56.
10. Herpertz S, Sass H, Favazza A. Impulsivity in self-mutilative behavior: psychometric and biological findings. J Psychiatr Res 1997; 31:451-65.
11. Norra C, Mrazek M, Tuchtenhagen F, et al. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatr Res 2003;37:23-33.
12. Tiihonen J, Kuikka JT, Bergstrom KA, et al. Single-photon emission tomography imaging of monoamine transporters in impulsive violent behaviour. Eur J Nucl Med 1997;24:1253-60.
13. Frankle WG, Lombardo I, New AS, et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity: a positron emission study with [11C]McN 5652. Am J Psychiatry 2005;162:915-23.
14. Lindstrom MB, Ryding E, Bosson P, et al. Impulsivity related to brain serotonin transporter binding capacity in suicide attempters. Eur Neuropsychopharmacol 2004;14:295-300.
15. Laruelle M, Baldwin RM, Malison RT, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993;13:295-309.
16. Oya S, Choi SR, Hou C, et al. 2-((2-((dimethylamino)methyl)-phenyl)thio)- 5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 2000;27:249-54.
17. Kung HF, Newman S, Choi SR, et al. 2-(2-(dimethylamino-methyl)phenoxy)-5- iodophenylamine: an improved serotonin transporter imaging agent. J Med Chem 2004;47:5258-64.
18. Newberg AB, Amsterdam JD, Wintering N, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med 2005;46:973-7.
19. Herold N, Uebelhack K, Franke L, et al. Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [(123)I]-ADAM. J Neural Transm 2006;113:659-70.
20. Wittchen HU, Zaudig M, Fydrich T. Strukturiertes Klinisches Interview für DSM-IV Achse I und II - SKID. Göttingen (Germany): Hogrefe; 1997.
21. Zanarini MC, Gunderson JG, Frankenburg FR, et al. The revised diagnostic interview for borderlines: discriminating BPD from other axis II disorders. J Pers Disord 1989;3:10-8.
22. American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures. Handbook of psychiatric measures. Washington: The Association; 2000. p. 691-93.
23. Koenigsberg HW, Anwunah I, New AS, et al. Relationship between depression and borderline personality disorder. Depress Anxiety 1999;10:158-67.
24. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
25. Catafau AM, Perez V, Penengo MM, et al. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med 2005;46:1301-9.
26. Sacher J, Asenbaum S, Klein N, et al. Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand. Int J Neuropsychopharmacol 2007;10:211-8.
27. Tatsch K, Asenbaum S, Bartenstein P, et al. European Association of Nuclear Medicine procedure guidelines for brain neurotransmission SPET using (123)I-labelled dopamine D(2) transporter ligands. Eur J Nucl Med Mol Imaging 2002;29:BP30-5.
28. Koch W, Radau PE, Hamann C, et al. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med 2005;46:1109-18.
29. Hill DL, Maurer CR Jr, Studholme C, et al. Correcting scaling errors in tomographic images using a nine degree of freedom registration algorithm. J Comput Assist Tomogr 1998;22:317-23.
30. Radau PE, Slomka PJ, Julin P, et al. Evaluation of linear registration algorithms for brain SPECT and the errors due to hypoperfusion lesions. Med Phys 2001;28:1660-8.
31. Hollander E, Stein DJ, DeCaria CM, et al. Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 1994;151:277-80.
32. Heinz A, Higley JD, Gorey JG, et al. In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am J Psychiatry 1998;155:1023-8.
33. Malison RT, Price LH, Berman R, et al. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998;44: 1090-8.
34. Tauscher J, Pirker W, Willeit M, et al. [123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol Psychiatry 2001;49:326-32.
35. Pogarell O, Hamann C, Popperl G, et al. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. Biol Psychiatry 2003;54:1406-13.
36. Hesse S, Barthel H, Hermann W, et al. Regional serotonin transporter availability and depression are correlated in Wilson's disease. J Neural Transm 2003;110:923-33.
37. Meyer JH, Houle S, Sagrati S, et al. Brain serotonin transporter binding potential measured with carbon 11-labeled DASB positron emission tomography: effects of major depressive episodes and severity of dysfunctional attitudes. Arch Gen Psychiatry 2004;61: 1271-9.
38. Meyer JH, McMain S, Kennedy SH, et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 2003;160:90-9.
39. Staley JK, Krishnan-Sarin S, Zoghbi S, et al. Sex differences in [123I]beta-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. Synapse 2001;41:275-84.
40. Rubinow DR, Schmidt PJ, Roca CA. Estrogen-serotonin interactions: implications for affective regulation. Biol Psychiatry 1998;44: 839-50.
41. Best SE, Sarrel PM, Malison RT, et al. Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle. Psychopharmacology (Berl) 2005;183:181-9.
42. Traskman-Bendz L, Asberg M, Schalling D. Serotonergic function and suicidal behavior in personality disorders. Ann N Y Acad Sci 1986;487:168-74.
43. Linnoila M, Virkkunen M, Scheinin M, et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci 1983;33: 2609-14.
44. Sekine Y, Ouchi Y, Takei N, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 2006;63:90-100.
45. Kish SJ, Furukawa Y, Chang LJ, et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? Nucl Med Biol 2005;32:123-8.